Video Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure for Myerlofibrosis: Real-World Assessment of Spleen, Symptoms, and Hematologic Response
News Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma